Bimzelx (Bimekizumab) For The Treatment Of Adult Onset PRP

Bimzelx (Bimekizumab) For The Treatment Of Adult Onset Pityriasis Rubra Pilaris: A Single Arm, Open?Label, Exploratory Trial

The purpose of this study is to valuate the clinical efficacy of Bimzelx therapy in adults with Pityriasis Rubra Pilaris.

Inclusion Criteria:

• Clinical and/or histopathological diagnosis of PRP
• Candidate for systemic therapy (PASI ≥ 10)
• Body surface area of involvement ≥ 10%
• Good general health as confirmed by medical history
• Patients who are willing and capable of cooperating to the extent and degree required by the protocol; and
• Patients who read and sign an approved informed consent for this study

Exclusion Criteria:

• Vulnerable study population
• Pregnant or nursing women
• Women planning a pregnancy within the study period
• Human immunodeficiency virus (HIV) positivity
• Known history of adverse reaction to Bimzelx
• Known history of hepatitis B, hepatitis C, or tuberculosis
• Personal or family history of inflammatory bowel disease